receiving adjuvant treatment for completely resected lung cancer. In addition to gross metastases and multiple lymph node disease extranodal tumour growth is regarded as advanced and unresectable disease.48 A recent study showed five year survivals in patients with N2 disease of 34% for those with intranodal invasion, but only 11% for those with extranodal invasion (p < 001).9 Clinicians obviously assume that extranodal tumour growth is a clearcut histological feature and a counterpart of intranodal tumour extension. In a previous study7 it was even stated that, "it was easy to classify lymphatic metastases as intranodal and perinodal because of the pathologists' detailed and clear descriptions of the resected tissue". However, criteria for these growth patterns are very ill defined and the reproducibility of these histological assessments should be regarded as questionable. The aim of the present study was to investigate the reproducibility of the histological features of intranodal and extranodal tumour growth in N2 metastasised NSCLC. The possibility of defining clear criteria for these growth patterns was also studied to improve this reproducibility.
The benefit of surgical resection in the presence of ipsilateral mediastinal lymph node metastases (N2 disease) in non-small cell lung carcinoma (NSCLC) is controversial.' If diagnosed preoperatively less than 10% of all patients with N2 disease treated surgically survive five years. 2 Only if lymph node metastasis discovered at mediastinoscopy is solitary, ipsilateral, and intranodal (minimal N2 disease) are patients potential candidates for surgery. ' Five year survivals of 20% or more have been reported after complete surgical resection in patients with minimal N2 disease. 3 Patients with minimal N2 disease have also been accepted as a special group in the European Organisation on Research and Treatment of Cancer study (08861) receiving adjuvant treatment for completely resected lung cancer. In addition to gross metastases and multiple lymph node disease extranodal tumour growth is regarded as advanced and unresectable disease.48 A recent study showed five year survivals in patients with N2 disease of 34% for those with intranodal invasion, but only 11% for those with extranodal invasion (p < 001).9 Clinicians obviously assume that extranodal tumour growth is a clearcut histological feature and a counterpart of intranodal tumour extension. In a previous study7 it was even stated that, "it was easy to classify lymphatic metastases as intranodal and perinodal because of the pathologists' detailed and clear descriptions of the resected tissue". However, criteria for these growth patterns are very ill defined and the reproducibility of these histological assessments should be regarded as questionable. The aim of the present study was to investigate the reproducibility of the histological features of intranodal and extranodal tumour growth in N2 metastasised NSCLC. The possibility of defining clear criteria for these growth patterns was also studied to improve this reproducibility.
Methods
Original histological sections of all mediastinal lymph node metastases obtained by mediastinal lymph node dissection (n = 82, 42 cases) or by mediastinoscopy (n = 62, 38 cases) in patients with NSCLC operated on between 1986 and 1992 were available for review.'0 In a pilot study the haematoxylin and eosin stained sections were classified independently by three pathologists as to tumour extension: intranodal, extranodal, or indefinite. Strict criteria for the different growth patterns were not used in this pilot study. The diagnoses of the three pathologists were compared and the agreement of the group was statistically evaluated by means of Cohen's K statistic." 12 The interobserver agreement was analysed separately for the dissected lymph nodes on the one hand and for the mediastinoscopic biopsy specimens on the other.
Strict criteria for three different categories of tumour extension were proposed at a consensus meeting, based on the experiences in the pilot study: tumour extension was classified as extranodal when either tumour pene--. . 1 (fig 1) , or the tissue sample contained fat tissue with tumour infiltration, or when tumour cells were present in the lumen of a vessel that was unequivocally a vein. A lymph node metastasis was regarded as being intranodal when either a completely removed lymph node was present for evaluation and there were no signs of extranodal tumour growth, or when a lymph node fragment was present but the metastasis was completely surrounded by lymphatic tissue or bordered by an intact capsule. Tumour extension was classified as indefinite in those tissue samples that did not meet the criteria for either extranodal or intranodal tumour extension.
Finally, after one year the sections of the lymph node metastases were re-evaluated independently by the pathologists for a second time, but now using the criteria defined in the consensus meeting. Interobserver agreement was again evaluated by means of Cohen's K statistic. The percentages represent the mean of three observers. The second part of the present study started with the definition of criteria for intranodal and extranodal growth, as these have been poorly defined. In metastasised breast cancer where extranodal tumour extension is accepted as integral part of TNM staging, extranodal disease is regarded as being present when there are demonstrable tumour cells outside the confines of the lymph node capsule after capsular penetration or destruction by the tumour.'1-6 Obviously, it is assumed that a metastasis is intranodal when signs of extranodal growth are absent.
Although this definition appears clear at first sight, it actually fails to take into account what the consequences are for classification if only a part of a lymph node is present in the histological section (instead of a complete node). Moreover, it does not clarify how vascular or lymphatic permeation should be regarded, and how the presence of tumour infiltration in hilar (efferent) lymphatic vessels should be judged. In the present study there was often no complete lymph node available for evaluation. If this was thought to be due to tissue processing in the Department of Pathologyfor example, a straight cut edge (fig 2) to the missing part of the lymph node, or when there was the impression that the tissue was not cut deeply enough-it was assumed that the growth pattern in the missing part was no different from that in the other part. Consequently, if no signs of extranodal growth were present, metastases were classified (at the second examination) as intranodal and not as indefinite. When tumour cells were found in the lumen of either an extranodal or a hilar (efferent) lymph vessel, this was regarded as being not truely extranodal, but intranodal, as these tumour cells were still situated within the lymphatic system. In the EORTC trial referred to earlier lymphatic permeation was regarded as extranodal tumour growth. Nevertheless, cases with tumour cells in efferent lymphatics could represent a special group, because this has prognostic implications in patients with breast cancer. ' 
